Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Breast Neoplasms 15Neoplasms 4Neoplasm Metastasis 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Diseases 2Tuberous Sclerosis 1Thoracic Neoplasms 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Obesity 1Neuroendocrine Tumors 1Neoplasms by Site 1Lymphoma 1Lung Neoplasms 1Lung Diseases 1Kidney Neoplasms 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Hepatocellular 1Carcinoma, Bronchogenic 1Bronchial Neoplasms 1Breast Neoplasms, Male 1Acrocephalosyndactylia 1

Interventions

radiprodil 2Sirolimus 2exemestane 1Melatonin 1Itraconazole 1Injections 1Everolimus 1Carbamazepine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Tuberous Sclerosis × exemestane × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡